Biofrontera AG Logo

Biofrontera AG

Biopharma firm specializing in photodynamic therapy for dermatological conditions like actinic keratosis.

B8F | F

Overview

Corporate Details

ISIN(s):
DE000A409625 (+2 more)
LEI:
391200D6GFSVFGFQTL13
Country:
Germany
Address:
Hemmelrather Weg 201, 51377 Leverkusen
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The company focuses on innovative products for the care, protection, and treatment of skin conditions. Its core expertise is in photodynamic therapy (PDT), offering a combination of its prescription drug, Ameluz®, and its medical device, the RhodoLED® lamp, primarily for the treatment of actinic keratosis. The company's portfolio also includes topical antibiotics and other medical cosmetic products.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-10 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2025 bis zum 30.06.2025
German 6.3 KB
2025-05-13 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 205.3 KB
2025-05-09 00:00
Regulatory News Service
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 138.8 KB
2025-04-17 15:05
Pre-Annual General Meeting Information
Biofrontera AG: Bekanntmachung der Einberufung zur Hauptversammlung am 28.05.20…
German 44.5 KB
2025-04-17 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 14.04.2025 bis zum 13.04.2029
German 6.5 KB
2024-09-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2024 bis zum 30.06…
German 264.3 KB
2024-09-26 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-07-21 00:00
Legal Proceedings Report
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
German 11.8 KB
2024-05-02 00:00
Regulatory News Service
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 132.6 KB
2024-05-02 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 185.6 KB
2024-04-29 00:00
Annual Report
English 4.0 MB
2024-04-24 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.3 KB
2023-08-31 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG für den Zeitraum vom 01.01.2023 bis zum 30.06…
German 236.4 KB
2023-08-18 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2023 bis zum 30.06.2023
German 6.4 KB
2023-05-02 00:00
Regulatory News Service
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 539.4 KB

Automate Your Workflow. Get a real-time feed of all Biofrontera AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Biofrontera AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Biofrontera AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-03-24 Deutsche Balaton Aktiengesellschaft Close relation Buy None 7,366.00 EUR
2023-03-24 Deutsche Balaton Aktiengesellschaft Close relation Buy None 381.00 EUR
2023-03-20 Deutsche Balaton Aktiengesellschaft Close relation Buy None 7,503.16 EUR
2023-03-13 NEON Equity AG Close relation Buy None 30,627.00 EUR
2023-03-13 Deutsche Balaton Aktiengesellschaft Close relation Buy None 6,290.31 EUR
2023-03-13 Deutsche Balaton Aktiengesellschaft Close relation Buy None 635.00 EUR
2023-03-13 TO Holding 1 GmbH Close relation Buy None 575.00 EUR
2023-03-10 Deutsche Balaton Aktiengesellschaft Close relation Buy None 6,718.30 EUR
2023-03-08 Adenauer, Dr. Sven-Georg Other Buy None 140,000.00 EUR
2023-03-06 Deutsche Balaton Aktiengesellschaft Close relation Buy None 152.40 EUR

Peer Companies

Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS

Talk to a Data Expert

Have a question? We'll get back to you promptly.